证券代码：601089 证券简称：福元医药 公告编号：临 2025-056 北京福元医药股份有限公司 关于全资子公司营业执照变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 北京福元医药股份有限公司(以下简称"公司") 的全资子公司福 元药业有限公司于近日对经营范围进行了变更，并完成了工商变更登 记手续，取得了宣城市市场监督管理局换发的《营业执照》。变更后 《营业执照》基本登记信息如下： 法定代表人：黄河 注册资本：柒仟伍佰万圆整 成立日期：2001 年 09 月 03 日 住所：安徽省宣城市经济技术开发区 经营范围：许可项目：药品生产；药品委托生产；药品进出口； 消毒剂生产（不含危险化学品）；保健食品生产；化妆品生产；药品 互联网信息服务；供电业务（依法须经批准的项目，经相关部门批准 后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件 为准）一般项目：日用化学产品制造；日用化学产品销售；化妆品批 发；化妆品零售；互联网销售（除销售需要许可的商品）；技术服务、 技术开发、技术咨询、技术交流、技术转让、技术 ...

资金流向方面，今日主力资金净流出2896.47万元，占比成交额5.26%。其中，超大单净流出1086.97万 元、占成交额1.97%，大单净流出1809.50万元、占成交额3.29%，中单净流出流入1157.64万元、占成交 额2.1%，小单净流入1738.82万元、占成交额3.16%。 通过天眼查大数据分析，北京福元医药股份有限公司共对外投资了3家企业，参与招投标项目5000次， 知识产权方面有商标信息214条，专利信息142条，此外企业还拥有行政许可148个。 来源：金融界 福元医药最新一期业绩显示，截至2025一季报，公司营业总收入8.30亿元、同比增长3.46%，归属净利 润1.31亿元，同比减少1.47%，扣非净利润1.22亿元，同比减少1.16%，流动比率2.737、速动比率 2.441、资产负债率24.29%。 天眼查商业履历信息显示，北京福元医药股份有限公司，成立于1999年，位于北京市，是一家以从事医 药制造业为主的企业。企业注册资本48000万人民币，实缴资本48000万人民币。公司法定代表人为黄 河。 金融界消息 截至2025年8月12日收盘，福元医药（601089）报收于30.64元， ...

New Stock Listings - Tianfu Long (603406) issued at a price of 23.60[1] - Youli Intelligent (920007) issued at a price of 23.99[1] Rights Issues and Announcements - China Heavy Industry (601989) cash option declaration period from August 13, 2025[1] - China Shipbuilding (600150) acquisition request period from August 13 to August 15, 2025[1] - Shenkai Co., Ltd. (002633) offer declaration period from July 29 to August 27, 2025[1] - ST Kelly (300326) offer period from July 17 to August 15, 2025[1] - Fushun Special Steel (600399) offer period from August 12 to September 10, 2025[1] Abnormal Fluctuations - Multiple stocks reported abnormal fluctuations, including *ST Yushun (002289) and Changcheng Military Industry (601606)[2][3] - Notable fluctuations also reported for companies like Li De Man (300289) and Dongjie Intelligent (300486)[3]

Market Overview - On August 8, the chemical pharmaceutical sector rose by 0.24% compared to the previous trading day, with Lianhuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3635.13, down 0.12%, while the Shenzhen Component Index closed at 11128.67, down 0.26% [1] Stock Performance - Notable declines in individual stocks include: - Shanghai Yizhong: closed at 72.23, down 5.42% with a trading volume of 80,000 shares and a turnover of 573 million yuan - Yifang Bio: closed at 39.80, down 5.37% with a trading volume of 203,000 shares and a turnover of 818 million yuan - Qianhong Pharmaceutical: closed at 10.19, down 4.77% with a trading volume of 1,197,800 shares and a turnover of 1.23 billion yuan [1] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 230 million yuan from institutional investors and a net outflow of 93.16 million yuan from retail investors, while retail investors saw a net inflow of 323 million yuan [1] - Key stocks with significant capital flow include: - Meinuohua: net inflow of 236 million yuan from institutional investors, with a 18.01% share - Lianhuan Pharmaceutical: net inflow of 197 million yuan from institutional investors, with a 13.40% share [2] - Other notable stocks include Han Yu Pharmaceutical and Bo Rui Pharmaceutical, with net inflows of 171 million yuan and 131 million yuan from institutional investors, respectively [2]

Group 1 - The stock price of Fuyuan Pharmaceutical as of August 7, 2025, is 26.92 yuan, down by 1.13 yuan or 4.03% from the previous trading day [1] - The opening price on the same day was 28.72 yuan, with a highest point of 28.99 yuan and a lowest point of 26.70 yuan, resulting in a trading volume of 274,783 hands and a transaction amount of 761 million yuan [1] - Fuyuan Pharmaceutical operates in the chemical pharmaceutical sector, focusing on drug research, production, and sales, with a product line covering multiple therapeutic areas and a business presence in Beijing [1] Group 2 - On August 7, the net outflow of main funds was 11.06 million yuan, with a cumulative net outflow of 21.21 million yuan over the past five trading days [1] - During intraday trading, the stock experienced rapid fluctuations, including a rebound of over 2% within five minutes at 9:53 AM, followed by a decline of over 2% within five minutes at 9:40 AM [1]

Group 1 - The innovative drug concept stocks experienced significant upward movement, with Rundu Co., Ltd. hitting the daily limit increase [1] - Haitian Pharmaceutical and Sunshine Nuohuo both rose over 10%, indicating strong market interest [1] - Other companies such as Huaren Health, Fuyuan Pharmaceutical, and Guangsheng Tang also saw notable gains, reflecting a broader trend in the sector [1]

Group 1 - The stock price of Fuyuan Pharmaceutical closed at 28.78 yuan on August 5, 2025, down 1.40% from the previous trading day, with a trading range of 7.64% [1] - The highest price during the day reached 30.00 yuan, while the lowest was 27.77 yuan, with a trading volume of 340,600 hands and a transaction amount of 980 million yuan, resulting in a turnover rate of 7.10% [1] - The company is primarily engaged in chemical pharmaceuticals and is registered in Beijing, with a total market capitalization of 13.814 billion yuan and a price-to-earnings ratio of 26.44 times, along with a price-to-book ratio of 4.01 times [1] Group 2 - On August 5, the net outflow of main funds was 131 million yuan, accounting for 0.95% of the circulating market value; however, over the past five trading days, there has been an overall net inflow of 20.8001 million yuan [1]

New Stock Issuance - The new stock issuance for Zhigao Machinery (证券代码: 920101) is priced at 17.41 CNY per share, effective from August 5, 2025[1] - China Heavy Industry (证券代码: 601989) has a cash option declaration period from August 13, 2025[1] - China Shipbuilding (证券代码: 600150) has a buyback request period from August 13 to August 15, 2025[1] Offer and Acquisition Periods - Shenkou Co., Ltd. (证券代码: 002633) has a tender offer period from July 29 to August 27, 2025[1] - ST Kelly (证券代码: 300326) has a tender offer period from July 17 to August 15, 2025[1] - Happiness Blue Ocean (证券代码: 300528) has a significant announcement on July 30, 2025[1] Market Volatility - There are reports of severe abnormal fluctuations for Tibet Tourism (证券代码: 600749) as of July 31, 2025[1] - ST Suwu (证券代码: 600200) also reported significant volatility on July 30, 2025[1] - The stock of ST YaTai (证券代码: 000691) is under observation for abnormal trading activities as of August 5, 2025[1]

Key Points - The article discusses the recent trends in the A-share market, including new stock offerings and regulatory updates affecting investors [1][4][5][6][8] - It highlights the increase in new A-share accounts and the implications of new tax regulations on overseas stock trading [4][5] - The article also covers various company news, including stock repurchases and strategic plans for future growth [10][18][19][20][22] Group 1: Market Trends - On August 4, the Shanghai Stock Exchange reported that 1.9636 million new A-share accounts were opened in July, a nearly 20% increase from June and over 70% year-on-year [4] - The article mentions the new tax regulations requiring individuals to declare and pay taxes on overseas stock trading income, with a 20% tax rate applicable [5] - The revised Anti-Money Laundering Law will take effect on January 1, 2025, with new guidelines for financial institutions [6] Group 2: Company News - Zhi Gao Machinery has a new stock offering with a subscription code of 920101 and an issue price of 17.41 yuan per share, with a subscription limit of 1.0203 million shares [1] - Nanjing Bank's shareholder, Nanjing High-Tech, increased its stake to 9% [18] - Guizhou Moutai has repurchased 3.4517 million shares for a total cost of 5.301 billion yuan [19] - CATL has repurchased 6.641 million shares, totaling 1.551 billion yuan [20] - XGIMI Technology is planning to issue H-shares and list on the Hong Kong Stock Exchange [22]

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price increase of 20% over three consecutive trading days from July 31 to August 4, 2025, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [2][3]. Group 1: Stock Trading Abnormality - The company's stock price increased by a cumulative 20% over three consecutive trading days, indicating abnormal trading activity [2][3]. - The company conducted a self-examination and confirmed that there were no undisclosed significant matters related to the stock price fluctuation [4]. Group 2: Company Operations and Major Events - The company's production and operational activities are reported to be normal, with no significant changes in the internal or external environment [4]. - The company confirmed that its controlling shareholder and actual controller have no undisclosed significant matters, including major asset restructuring or significant transactions [5]. Group 3: Market Sentiment and Media Reports - There has been increased market attention on the company's innovative drug business, particularly following the announcement of the clinical trial approval for its innovative drug FY101 [6]. - The company is currently in the I phase of clinical trials for FY101, with significant uncertainty regarding the trial's success [6]. Group 4: Other Relevant Matters - The company has not identified any other significant events that could impact its stock price, and there were no stock trades by directors, supervisors, or senior management during the abnormal trading period [7]. - The board of directors confirmed that there are no undisclosed matters that could significantly affect the company's stock price [11].